BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Huiyoujing (janagliflozin) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Huiyoujing (janagliflozin)\, from Clinica
 lTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07244003-459@assetmemo.bio
DTSTAMP:20261121T005726Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Huiyoujing (janagliflozin): Phase 4 readout est. (NCT07244003)
DESCRIPTION:Huiyoujing (janagliflozin)\, phase 4\, Type 2 Diabetes.\nStudy:
  Efficacy and Safety of the Met+SGLT-2i+GLP-1RA in Patients With Type 2 Di
 abetes With Poor Glycemic Control\nEstimated primary completion: 31 Decemb
 er 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/janagliflozi
 n#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 244003
URL:https://assetmemo.bio/drug/janagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07116928-459@assetmemo.bio
DTSTAMP:20261121T005726Z
DTSTART;VALUE=DATE:20311030
DTEND;VALUE=DATE:20311031
SUMMARY:Huiyoujing (janagliflozin): Phase 4 readout est. (NCT07116928)
DESCRIPTION:Huiyoujing (janagliflozin)\, phase 4\, Type 2 Diabetes.\nStudy:
  Ganagliflozin on the Progression of Kidney Disease in Subjects With Type 
 2 Diabetes Mellitus and Chronic Kidney Disease\nEstimated primary completi
 on: 30 October 2031. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 janagliflozin#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07116928
URL:https://assetmemo.bio/drug/janagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
